- Home
- PROP vs PRQR Comparison
PROP vs PRQR Comparison
Compare PROP & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROP
- PRQR
- Stock Information
- Founded
- PROP 2001
- PRQR 2012
- Country
- PROP United States
- PRQR Netherlands
- Employees
- PROP 19
- PRQR N/A
- Industry
- PROP Investment Bankers/Brokers/Service
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PROP Finance
- PRQR Health Care
- Exchange
- PROP Nasdaq
- PRQR Nasdaq
- Market Cap
- PROP 168.7M
- PRQR 179.1M
- IPO Year
- PROP N/A
- PRQR 2014
- Fundamental
- Price
- PROP $3.97
- PRQR $1.93
- Analyst Decision
- PROP Strong Buy
- PRQR Strong Buy
- Analyst Count
- PROP 4
- PRQR 7
- Target Price
- PROP $8.75
- PRQR $9.00
- AVG Volume (30 Days)
- PROP 839.6K
- PRQR 271.0K
- Earning Date
- PROP 08-15-2025
- PRQR 08-07-2025
- Dividend Yield
- PROP N/A
- PRQR N/A
- EPS Growth
- PROP N/A
- PRQR N/A
- EPS
- PROP N/A
- PRQR N/A
- Revenue
- PROP $21,529,000.00
- PRQR $21,212,711.00
- Revenue This Year
- PROP $5,974.95
- PRQR N/A
- Revenue Next Year
- PROP $26.36
- PRQR N/A
- P/E Ratio
- PROP N/A
- PRQR N/A
- Revenue Growth
- PROP N/A
- PRQR 85.91
- 52 Week Low
- PROP $3.35
- PRQR $1.07
- 52 Week High
- PROP $12.30
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PROP 48.93
- PRQR 60.77
- Support Level
- PROP $3.87
- PRQR $1.77
- Resistance Level
- PROP $4.07
- PRQR $2.03
- Average True Range (ATR)
- PROP 0.20
- PRQR 0.10
- MACD
- PROP 0.03
- PRQR 0.01
- Stochastic Oscillator
- PROP 50.88
- PRQR 72.97
About PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.